These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37182286)

  • 41. EPS8 regulates an NLRP3 inflammasome-independent caspase-1 activation pathway in monosodium urate crystal-treated RAW264.7 macrophages.
    Chuang JP; Kao CY; Lee JC; Ling P; Maa MC; Leu TH
    Biochem Biophys Res Commun; 2020 Sep; 530(3):487-493. PubMed ID: 32595041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diallyl trisulfide inhibits monosodium urate-induced NLRP3 inflammasome activation via NOX3/4-dependent mitochondrial oxidative stress in RAW 264.7 and bone marrow-derived macrophages.
    Kim MY; Bang E; Hwangbo H; Ji SY; Kim DH; Lee H; Park C; Hong SH; Kim GY; Choi YH
    Phytomedicine; 2023 Apr; 112():154705. PubMed ID: 36796188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis.
    Kodithuwakku ND; Pan M; Zhu YL; Zhang YY; Feng YD; Fang WR; Li YM
    J Ethnopharmacol; 2013 Dec; 150(3):1071-9. PubMed ID: 24161431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare.
    Popov D; Jain L; Alhilali M; Dalbeth N; Poulsen RC
    FASEB J; 2023 Jun; 37(6):e22940. PubMed ID: 37243314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human proteoglycan-4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of cytokines and chemokines in human and murine macrophages.
    Qadri M; Jay GD; Zhang LX; Wong W; Reginato AM; Sun C; Schmidt TA; Elsaid KA
    Arthritis Res Ther; 2018 Aug; 20(1):192. PubMed ID: 30157934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
    Liang G; Nie Y; Chang Y; Zeng S; Liang C; Zheng X; Xiao D; Zhan S; Zheng Q
    Phytomedicine; 2019 Jun; 59():152772. PubMed ID: 31005813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ameliorative Effects of Cardamonin on Monosodium Urate-Induced Gouty Arthritis through Inhibiting NLRP3 Inflammasome Mediation.
    Wang CC; Lu JW; Peng YJ; Lee CH; Lee HS; Chu YH; Huang CJ; Ho YJ; Liu FC; Wu CC
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577821
    [No Abstract]   [Full Text] [Related]  

  • 48. Development of a multivariable improvement measure for gout.
    Schlesinger N; Edwards NL; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
    J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune and inflammatory mechanisms and therapeutic targets of gout: An update.
    Liu W; Peng J; Wu Y; Ye Z; Zong Z; Wu R; Li H
    Int Immunopharmacol; 2023 Aug; 121():110466. PubMed ID: 37311355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanosensitive TRPV4 is required for crystal-induced inflammation.
    Lan Z; Chen L; Feng J; Xie Z; Liu Z; Wang F; Liu P; Yue X; Du L; Zhao Y; Yang P; Luo J; Zhu Z; Hu X; Cao L; Lu P; Sah R; Lavine K; Kim B; Hu H
    Ann Rheum Dis; 2021 Dec; 80(12):1604-1614. PubMed ID: 34663597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3-Driven Inflammation and Gouty Arthritis.
    Yang G; Lee HE; Moon SJ; Ko KM; Koh JH; Seok JK; Min JK; Heo TH; Kang HC; Cho YY; Lee HS; Fitzgerald KA; Lee JY
    Arthritis Rheumatol; 2020 Jul; 72(7):1192-1202. PubMed ID: 32134203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Refractory gout: what is it and what to do about it?
    Fels E; Sundy JS
    Curr Opin Rheumatol; 2008 Mar; 20(2):198-202. PubMed ID: 18349751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of NLRP3 in the pathogenesis and treatment of gout arthritis.
    Liu YR; Wang JQ; Li J
    Front Immunol; 2023; 14():1137822. PubMed ID: 37051231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7.
    Kim SK; Choe JY; Park KY
    Biochem Biophys Res Commun; 2019 Sep; 517(2):338-345. PubMed ID: 31358323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
    Meng ZQ; Tang ZH; Yan YX; Guo CR; Cao L; Ding G; Huang WZ; Wang ZZ; Wang KD; Xiao W; Yang ZL
    Am J Chin Med; 2014; 42(6):1471-83. PubMed ID: 25384446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in pharmacotherapy for the treatment of gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.